Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, has announced that Hong Kong Science and Technology Parks Corporation (HKSTP) has awarded maximum amount of HK$8 million matching funding to Immuno Cure under the Clinical Translational Catalyst programme (CTC Programme) for conducting the Phase 1 Clinical Trial of ICVAX, a therapeutic vaccine against HIV/AIDS.
The CTC Programme funding of HK$8 million will be drawn down by Immuno Cure in the next 27 months in various tranches according to the progress of the clinical trial of ICVAX.
Immuno Cure previously received the University-Industry Collaboration Programme and Cash Rebate Scheme funding of some HK$8.4 million from the Government
